These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22313057)

  • 1. HPLC assay and pharmacokinetics and tissue distribution study of glycyrrhetinic acid liposomes modified with galactosylated lipid.
    Guo BH; Cheng Y; Wu W; Lin LP; Lin DH
    J Liposome Res; 2012 Jun; 22(2):120-7. PubMed ID: 22313057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced distribution and extended elimination of glycyrrhetinic acid in mice liver by mPEG-PLA modified (mPEGylated) liposome.
    Li J; Yu H; Li S; Wang GJ
    J Pharm Biomed Anal; 2010 Apr; 51(5):1147-53. PubMed ID: 20005656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of galactose-modified liposomes by a nonaqueous enzymatic reaction.
    Guo BH; Cheng Y; Lin LP; Lin DH; Wu W
    J Liposome Res; 2011 Sep; 21(3):255-60. PubMed ID: 21545336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells.
    Lin J; Wang X; Wu Q; Dai J; Guan H; Cao W; He L; Wang Y
    Int J Pharm; 2014 Feb; 462(1-2):11-8. PubMed ID: 24374609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution and pulmonary targeting studies of cefpiramide sodium-loaded liposomes.
    Sun Q; Shi M; Shao W; Shi Y; Xi Y; Huang G
    J Drug Target; 2011 Jan; 19(1):49-55. PubMed ID: 20205530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifying glycyrrhetinic acid liposomes with liver-targeting ligand of galactosylated derivative: preparation and evaluations.
    Chen J; Chen Y; Cheng Y; Gao Y; Zheng P; Li C; Tong Y; Li Z; Luo W; Chen Z
    Oncotarget; 2017 Nov; 8(60):102046-102066. PubMed ID: 29254224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo studies of galactose-modified liver-targeting liposomes.
    Guo B; Cheng Y; Li N; Li X; Jin M; Li T; Li J
    J Drug Target; 2013 Apr; 21(3):257-264. PubMed ID: 23163746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of mPEG-PLA modified liposomes loaded glycyrrhetinic acid.
    Lu Y; Li J; Wang G
    Int J Pharm; 2008 May; 356(1-2):274-81. PubMed ID: 18304766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycyrrhetinic Acid Liposomes Containing Mannose-Diester Lauric Diacid-Cholesterol Conjugate Synthesized by Lipase-Catalytic Acylation for Liver-Specific Delivery.
    Chen J; Chen Y; Cheng Y; Gao Y
    Molecules; 2017 Sep; 22(10):. PubMed ID: 28946644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid.
    Mao SJ; Bi YQ; Jin H; Wei DP; He R; Hou SX
    Pharmazie; 2007 Aug; 62(8):614-9. PubMed ID: 17867558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
    Li J; Xu H; Ke X; Tian J
    J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
    Tian J; Wang L; Wang L; Ke X
    Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced transdermal delivery of 18β-glycyrrhetic acid via elastic vesicles: in vitro and in vivo evaluation.
    Li S; Qiu Y; Zhang S; Gao Y
    Drug Dev Ind Pharm; 2012 Jul; 38(7):855-65. PubMed ID: 22077323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and
    Zhou T; Tang X; Zhang W; Feng J; Wu W
    Drug Deliv; 2019 Dec; 26(1):673-679. PubMed ID: 31266376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation.
    Chen J; Jiang H; Wu Y; Li Y; Gao Y
    Drug Des Devel Ther; 2015; 9():2265-75. PubMed ID: 25945038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
    Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z
    Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution.
    Wang J; Huang G
    Drug Deliv; 2011 Nov; 18(8):631-8. PubMed ID: 22111976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preparation and in vivo study of liposomes mediated by glycyrrhetinic acid derivative ligand 18-GA-Gly].
    Jin S; Wang XL; Li G
    Zhongguo Zhong Yao Za Zhi; 2017 Nov; 42(21):4120-4126. PubMed ID: 29271149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.
    Wang HW; Jiang PL; Lin SF; Lin HJ; Ou KL; Deng WP; Lee LW; Huang YY; Liang PH; Liu DZ
    Acta Biomater; 2013 Mar; 9(3):5681-8. PubMed ID: 23159567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.